Clinical Practice Guidelines for the Diagnosis and Treatment of Scabies in Korea:Part 2. Treatment and Prevention
- Author:
Jin PARK
1
;
Soon-Hyo KWON
;
Young Bok LEE
;
Hei Sung KIM
;
Jie Hyun JEON
;
Gwang Seong CHOI
;
Author Information
1. Department of Dermatology, Jeonbuk National University Medical School, Jeonju, Korea
- Publication Type:Reveiw Article
- From:Korean Journal of Dermatology
2023;61(8):463-471
- CountryRepublic of Korea
- Language:English
-
Abstract:
For all suspected, clinical, or confirmed cases of scabies, treatment should be initiated. Affected patients should be adequately isolated, and high-risk groups with close contact histories should be treated irrespective of their symptoms. Optimal treatment strategies can be selected based on age, clinical subtype, and patient’s health status. In Korea, commercially available preparations for scabies treatment include topical 5% permethrin, topical 10% crotamiton, and oral ivermectin. Topical 5% permethrin is the first-line selective treatment for both classic and crusted scabies. Alternative treatments are topical 10% crotamiton and oral ivermectin. Following treatment completion, a follow-up visit at 2 and 4 weeks is recommended to monitor therapeutic response. Treatment failure is considered when scabies mites or burrows are detected, upon development of new clinical characteristics, or upon aggravation of pruritus. Scabies itch should be adequately managed with emollients, oral antihistamines, and topical corticosteroids. Preventive measures, including personal hygiene, patient education, and environmental control should be rendered to reduce the transmission of scabies.
